You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK):終止與阿斯利康製藥推廣合作
格隆匯 01-04 18:08

格隆匯1月4日丨君實生物(01877.HK)公佈,2021年2月28日,公司與阿斯利康製藥有限公司(以下簡稱"阿斯利康製藥"、"推廣方")簽署了《獨家推廣協議》(以下簡稱"原協議"),公司授予阿斯利康製藥特瑞普利單抗注射液(商品名:拓益®)在中國大陸地區後續獲批上市的泌尿腫瘤領域適應症的獨家推廣權,以及所有獲批適應症在非核心城市區域的獨家推廣權。公司繼續負責核心城市區域除泌尿腫瘤領域適應症之外的其他獲批適應症的推廣。

隨着公司自建的商業化團隊逐步成熟,特瑞普利單抗注射液更多適應症成功納入最新版國家醫保目錄,為更好地落實公司下一發展階段的產品商業化推廣策略,積極應對未來的市場競爭格局,經雙方友好協商,2021年12月31日,公司與阿斯利康製藥簽署了《獨家推廣協議之終止協議》(以下簡稱"終止協議"),原協議自2022年1月1日(以下簡稱"終止日")起終止,公司收回原協議約定的特瑞普利單抗注射液推廣權。

公吿稱,特瑞普利單抗注射液自上市以來,銷量主要集中於核心城市區域,非核心城市區域的銷量佔整體銷量比例較小。此外,《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021版)》新增納入特瑞普利單抗注射液的兩項適應症,將有利於進一步推動該藥物的市場推廣、提升整體銷售規模,公司商業化團隊將繼續負責特瑞普利單抗注射液在中國大陸地區的全部推廣活動,並加強在非核心城市區域的推廣力度。此次終止推廣合作是基於雙方友好協商、審慎判斷並充分溝通後做出的決定,預計不會對公司財務狀況及經營成果構成重大不利影響,不會損害公司及股東的利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account